/
SPRY
$5.66-$0.20 (-3.43%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$559.1M
99M shares
52-week range
$5.35 – $18.00
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-0.43
ARS Pharmaceuticals, Inc. Common Stock
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
www.ars-pharma.com- Employees
- 159
- IPO / List date
- Nov 9, 2022
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds SPRY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Third Point LLCas of 2026-03-31 | 1,000,000 | $8.0M |
| Renaissance Technologiesas of 2024-09-30 | 15,800 | $229.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SPRY yet.
